Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Consensus "Hold" from five analysts (1 sell, 2 hold, 2 buy) with an average 12‑month price target of $8.67, and recent price targets ranging from $5 to $12.
• Financial/stock snapshot: Shares opened at $8.08 (near its 12‑month high of $8.60) with a $685M market cap, a negative trailing EPS (missed last quarter at $(0.14)), and analysts expect about ‑$0.50 EPS for the year.
• Business focus: Alpha Tau is developing Alpha DaRT, a targeted alpha‑radiation therapy for solid tumors, which is currently being evaluated in clinical studies for head & neck, skin and other cancers.

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $8.6667.

Several brokerages recently issued reports on DRTS. HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Piper Sandler reiterated a "neutral" rating and issued a $5.00 price target on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Zacks Research upgraded shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. Citigroup increased their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Monday.

Alpha Tau Medical Stock Up 2.3%

Shares of NASDAQ DRTS opened at $8.08 on Thursday. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $7.30 and a two-hundred day simple moving average of $5.84. The firm has a market capitalization of $685.35 million, a PE ratio of -15.25 and a beta of 1.04. Alpha Tau Medical has a 12 month low of $2.50 and a 12 month high of $8.60.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities analysts expect that Alpha Tau Medical will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new position in shares of Alpha Tau Medical in the 4th quarter worth about $48,000. Envestnet Asset Management Inc. purchased a new position in Alpha Tau Medical in the third quarter worth about $62,000. Bank of America Corp DE raised its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock worth $116,000 after buying an additional 17,500 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Alpha Tau Medical in the third quarter worth about $170,000. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.